Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (114)

II-001Edoardo Faggionato

Use of the Minimally-Invasive Oral Minimal Model to Quantify the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals with Type 1 Diabetes under Free-living Conditions

Wednesday 15:20-16:50

II-002Maite Garraza Obaldia

Semi-mechanistic model of pulmonary ventilation changes during propofol and remifentanil infusion as measured by minute-volume and transcutaneous pCO2.

Wednesday 15:20-16:50

II-003Anna Gebhard

Pharmacokinetic–pharmacodynamic modeling and treatment simulation of maintenance therapy for childhood acute lymphoblastic leukemia

Wednesday 15:20-16:50

II-004Eva Germovsek

A semi-mechanistic model of preclinical VSV-GP(-Luc) viral dynamics in blood and tumour

Wednesday 15:20-16:50

II-005Mohamed Gewily

Quantitative comparisons of Progressive Supranuclear Palsy rating scales versions using Item Response Theory modeling

Wednesday 15:20-16:50

II-006Stefano Giampiccolo

Supporting pharmacometrics applications by robust parameter estimation and identifiability analysis using hybrid Neural ODEs

Wednesday 15:20-16:50

II-007Asina Gijasi

Structural model development with compartmental pharmacokinetic models for a range of small molecule subcutaneous data

Wednesday 15:20-16:50

II-008Janice Goh

A model-informed framework for prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy

Wednesday 15:20-16:50

II-009Antonio Goncalves

Operating characteristics of TGI metrics to support early Phase Ib decisions in unresectable hepatocellular carcinoma patients based on an historical Phase III study (IMbrave150)

Wednesday 15:20-16:50

II-010Juan Guillermo Gonzalez Maffe

A Bayesian (P)K-TTE model to support early dose escalation decisions in phase 1 Oncology studies

Wednesday 15:20-16:50

II-011Verena Gotta

Anemia control under maintenance hemodialysis (HD) and association with long-term outcome in pediatric and adolescent patients – a real-world data analysis

Wednesday 15:20-16:50

II-012Katharina Martha Götz

The dose-response relationship of rituximab in pediatric patients after allogeneic hematopoietic stem cell transplantation – Model-informed evidence generation for a real-world problem

Wednesday 15:20-16:50

II-013Sebastiaan Goulooze

The drug titration paradox in the presence of intra-individual variation: can we estimate the true concentration-effect relationship?

Wednesday 15:20-16:50

II-014Sandra Grañana Castillo

Nintedanib physiologically based pharmacokinetic (PBPK) model to predict drug-drug interactions

Wednesday 15:20-16:50

II-015Silvia Grandoni

Do differences in PK defeat similarities in immune system in non-human primates? Pharmacokinetic modelling of standard of care antitubercular drugs in marmosets

Wednesday 15:20-16:50

II-016

Evaluating empirical dose-response relationships and dosing strategies of bacteriophage therapy using a mechanism-based modeling approach

Wednesday 15:20-16:50

II-017Jeremie Guedj

Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection

Wednesday 15:20-16:50

II-018Burak Kuersad Guenhan

Evaluating the utility of dose/exposure-response modeling for dose optimization in oncology

Wednesday 15:20-16:50

II-019Ikhlas Guermi

Development of a pharmacokinetic-pharmacodynamic model to describe blood hepcidin levels in patients with myelofibrosis and assess target engagement of zilurgisertib, an ALK2 inhibitor

Wednesday 15:20-16:50

II-020Berfin Gülave

Prediction of unbound partition coefficients at the blood-brain barrier (Kp,uu,BBB) using machine learning and its integration into a physiologically-based pharmacokinetic modeling workflow

Wednesday 15:20-16:50

II-021Yuchen Guo

pmxcopula – R package for copula-based covariate simulation

Wednesday 15:20-16:50

II-022Andrea Guzmán

Potential of Tacrolimus CYP3A5 genotyping to predict phenotype (C0/Dose/Weight ratio) and applicability of PBPK modelling to improve dosing strategies in paediatric kidney transplant recipients

Wednesday 15:20-16:50

II-023Sofia Guzzetti

A modelling framework for in vitro/in vivo translation of PROTACs PK/PD and PK/Efficacy: accelerating drug discovery of targeted protein degraders

Wednesday 15:20-16:50

II-024Jeongmin Ha

Physiologically based Pharmacokinetic and Pharmacodynamic modeling of Enzalutamide and N-desmethyl enzalutamide

Wednesday 15:20-16:50

II-025Nadja Haas

Pharmacometric analysis of symptom burden during anti-cancer drug therapy by a Markov modelling approach

Wednesday 15:20-16:50

II-026Felix Hammann

Informing BOHEMIA cluster randomized controlled trial ivermectin dose selection in healthy participants in Kenya

Wednesday 15:20-16:50

II-027Nina Hanke

Population pharmacokinetic-pharmacodynamic modeling of the iclepertin drug effect on hemoglobin levels

Wednesday 15:20-16:50

II-028Miriam Happ

Quantifying the impact of infection on murine antibiotic exposure in the framework of non-conventional treatment modalities within the FAIR study

Wednesday 15:20-16:50

II-029Niklas Hartung

A unified Rodgers et al. model for predicting tissue partitioning reveals the need for a theoretical derivation of the Lukacova et al. (Simulations Plus) model

Wednesday 15:20-16:50

II-030Huan He

Is the model predictive performance with von Willebrand factor superior to others? An external evaluation of population pharmacokinetic models for FVIII concentrate BAY 81-8973 in pediatric patients with haemophilia A

Wednesday 15:20-16:50

II-032Astrid Heida

Model-informed dose optimization of mycophenolic acid in pediatric renal transplant patients

Wednesday 15:20-16:50

II-033Niels Hendrickx

Evaluation of treatment effects in genetic ataxias using SARA score modelling: comparison of multiple trial designs by a large trial simulation framework

Wednesday 15:20-16:50

II-034Emilie Hénin

Population pharmacokinetics of MLT103 and determination of CYP2D6 polymorphism by mixture modelling

Wednesday 15:20-16:50

II-035Rasmus Henninger

Preclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis

Wednesday 15:20-16:50

II-036Maud Hennion

Population Pharmacokinetic Model of Ixodes ricinus-Contact Phase Inhibitor for patients with Spontaneous Intracerebral Haemorrhage

Wednesday 15:20-16:50

II-037Sara Carolina Henriques

Unveiling the Potential of Cmax ƒ2 Factor Applied to Pilot Bioavailability/Bioequivalence Studies

Wednesday 15:20-16:50

II-038Thomas Henthorn

Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled ?9-Tetrahydrocannabinol (THC) Cannabis Market Products in Occasional and Daily Users

Wednesday 15:20-16:50

II-039Maria Patricia Hernandez Mitre

Population pharmacokinetics of olanzapine and quetiapine in critically ill adults with delirium

Wednesday 15:20-16:50

II-040Yannick Hoffert

Model-informed intravenous-to-subcutaneous switching of infliximab in patients with inflammatory bowel diseases

Wednesday 15:20-16:50

II-042Ana Homšek

External evaluation of selected infliximab population pharmacokinetic models on patients with fistulizing Crohn’s disease

Wednesday 15:20-16:50

II-043Andrew Hooker

Generating uncertainty estimates in empirical forest plots

Wednesday 15:20-16:50

II-044Nathanaël Hozé

A multi-scale modelling framework to assess the relationship between SARS-CoV-2 viral load and transmission in household studies.

Wednesday 15:20-16:50

II-045Ziheng Hu

Choice of Exposure Metric in Exposure-Response Modeling

Wednesday 15:20-16:50

II-046Zhe Huang

Model-integrated bioequivalence method for highly variable drugs with long half-life: a simulation study comparing complete washout and incomplete washout designs

Wednesday 15:20-16:50

II-047Miao-Chan Huang

Application of physiologically-based kinetic (PBK) modeling in revealing the role of the bile-salt efflux pump (BSEP) in bosentan-induced cholestasis

Wednesday 15:20-16:50

II-048Zhonghui Huang

Development and evaluation of nlmixr2auto: Automated open-source model building

Wednesday 15:20-16:50

II-049Silvia Illamola

Population analysis of blood-brain barrier heterogeneity and correlation with imaging characteristics in individuals with central nervous system malignancies.

Wednesday 15:20-16:50

II-050Marjorie Imperial

Step-Wise Population Pharmacokinetic Modeling Approach to Characterize Complex Absorption of Lenacapavir Following SC Administration in Healthy Participants

Wednesday 15:20-16:50

II-051Ibrahim Ince

Qualification of the Open Systems Pharmacology PBPK modeling Platform for simulation of transporter Drug-Drug-Interactions

Wednesday 15:20-16:50

II-052Alberto Ippolito

PKPD model evaluating the ideal interplay between the PK and mechanism of activation of conditionally activated molecules

Wednesday 15:20-16:50

II-053Khalid Iqbal

A review of population PK and exposure-response models reported in FDA oncology submission documents

Wednesday 15:20-16:50

II-054Van der Feltz Isabella

Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis

Wednesday 15:20-16:50

II-055Ravi Kumar Jairam

Systemic and ocular physiologically based pharmacokinetic models for protein therapeutics in rabbits

Wednesday 15:20-16:50

II-056Ludvig Jakobsson

A frailty model for quantifying the association between CompEx risk and variation in lung function in asthma

Wednesday 15:20-16:50

II-057Masoud Jamei

Same Dissolution Profile – Different Virtual Bioequivalence (VBE) Outcome! Input-Dependent Propagation of Between Subject Variability (BSV) in Gut Physiology to Dissolution and VBE

Wednesday 15:20-16:50

II-058Alexander Janssen

Time-dependent random effects.

Wednesday 15:20-16:50

II-059Hyeseon Jeon

Comparative Study of Target Mediated Drug Disposition Approximation Methods Based on Validity Conditions: Application to Clinical Trial Studies

Wednesday 15:20-16:50

II-060SEONGMEE JEONG

Model informed dosage regimen optimization of anti-CD47 antibody using target-mediated drug disposition model.

Wednesday 15:20-16:50

II-061Xu Jiang

Population pharmacokinetic and pharmacodynamic analysis of granulocyte colony-stimulating factor (G-CSF) to optimize dose and timing for harvesting CD34+ cells

Wednesday 15:20-16:50

II-062Martin Johnson

Understanding onset and response of two key endpoints in Systemic Lupus Erythematosus

Wednesday 15:20-16:50

II-063Shreyas Joshi

A multiscale framework for predicting the evolution of SARS-CoV-2 in response to vaccination and interventions.

Wednesday 15:20-16:50

II-064Felix Jost

Towards pharmacokinetic profile predictions of small molecules using machine learning derived parameters and compartmental modeling

Wednesday 15:20-16:50

II-065Woojin Jung

Predicting lung exposure of intramuscular niclosamide as an antiviral agent against COVID-19 using power-law-based pharmacokinetic modeling

Wednesday 15:20-16:50

II-066Christos Kaikousidis

Quantification of model misspecification of population pharmacokinetic models by a machine learning postprocessing correction of the residual variability

Wednesday 15:20-16:50

II-067Melanie Karlsen

Identifying SHAP’s added value to PK covariate modeling on a small dataset

Wednesday 15:20-16:50

II-068Daniel Kaschek

Using the M3 Method in Exploratory Plots and in NCA

Wednesday 15:20-16:50

II-069Csaba Katai

An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies

Wednesday 15:20-16:50

II-070Takayuki Katsube

Application of Machine Learning Approach to Pharmacokinetic/Pharmacodynamic Analysis of Lusutrombopag

Wednesday 15:20-16:50

II-071Marija Kekic

Stochastic Gate Neural Networks for Automatic Covariate Selection in Pharmacometrics Population Modeling

Wednesday 15:20-16:50

II-072Allan Kengo

Population pharmacokinetic analysis of the drug interaction between ritonavir-boosted atazanavir and rifampicin

Wednesday 15:20-16:50

II-073Anne Keunecke

Case study of Exposure-Safety analysis in Phase 1 oncology – lessons learned

Wednesday 15:20-16:50

II-074Anisa Khan

Population pharmacokinetics of cenobamate and dose rationale for its use in paediatric patients affected by focal onset and primary generalized tonic-clonic seizures.

Wednesday 15:20-16:50

II-075Fenja Klima

Quantifying the impact of CYP2D6 allele activity on Z-endoxifen formation leveraging the multi-study CEPAM database: Towards treatment optimisation of tamoxifen

Wednesday 15:20-16:50

II-076Marian Klose

Machine learning-driven flattening of model priors: A comparative simulation study across multiple compounds

Wednesday 15:20-16:50

II-077

Population Pharmacokinetic/Pharmacodynamic Modelling of Cytokine Releasing Syndrome (CRS) Events during T cell Engager Therapy

Wednesday 15:20-16:50

II-078Simon Koele

Population pharmacokinetics and exposure-response of BTZ-043 for the treatment of tuberculosis.

Wednesday 15:20-16:50

II-079Simon Koele

Model-informed trial design for the malaria transmission blocking antibody TB31F

Wednesday 15:20-16:50

II-080Matthias König

Captopril in Focus: Establishing an Open Pharmacokinetic Dataset and PBPK Modeling

Wednesday 15:20-16:50

II-081Sjoerd Koopman

A revised population pharmacokinetic model for recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin

Wednesday 15:20-16:50

II-082Christina Kovar

A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions

Wednesday 15:20-16:50

II-083Anders Kristoffersson

Optimal design of a reduced sampling schedule for the characterization of prolactin dynamics in healthy male volunteers and its evaluation to the describe the pharmacodynamic effect of a prolactin antagonist in a single rising dose study

Wednesday 15:20-16:50

II-084Wojciech Krzyzanski

Gauss-Hermite cohort population estimates of between subject variability for sparse data

Wednesday 15:20-16:50

II-085Victoria Kulesh

A mechanistic model of thymocyte dynamics: a quantitative tool for predicting drug effects on thymic function

Wednesday 15:20-16:50

II-086Pietro Laddomada

Dose rationale and metrics of target exposure for tacrolimus and mycophenolate in paediatric patients undergoing solid organ transplantation

Wednesday 15:20-16:50

II-087Jennifer Lang

Development of a population pharmacokinetic/pharmacodynamic model of lepodisiran, a small interfering RNA targeting lipoprotein(a), in healthy adults

Wednesday 15:20-16:50

II-088Jonas Langeraert

Small molecule drug absorption in inflammatory bowel disease and current implementation in PBPK models.

Wednesday 15:20-16:50

II-089Emilie Langeskov

WB-PBPK-PD Modeling for Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs

Wednesday 15:20-16:50

II-090Anna Largajolli

Clinical Model-Based Meta-Analysis applied to Vaccine Development for SARS-CoV-2 Variants

Wednesday 15:20-16:50

II-091Sebastiano Lava

Study design optimization in paediatric rare diseases: a case study on empagliflozin in paediatric heart failure

Wednesday 15:20-16:50

II-092Alexandra Lavalley-Morelle

Extending the R open-source saemix package: a new tool for parametric joint models

Wednesday 15:20-16:50

II-093Jacob Leander

Simulation-based comparison of MMRM and dose-response MMRM for Ph2b dose-finding design in rheumatoid arthritis

Wednesday 15:20-16:50

II-094Hyunjung Lee

Predicting intrinsic clearance by the integration of deep learning-based drug-metabolic enzyme binding interactions on a canonical in vitro-in vivo extrapolation method

Wednesday 15:20-16:50

II-095Donghwan Lee

Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients with Population Pharmacoki-netics and Monte-Carlo Simulation

Wednesday 15:20-16:50

II-096Apolline Lefevre

Uncoupling tumor cell killing and cytokine release following T-cell engager administration with a mechanistic PKPD model

Wednesday 15:20-16:50

II-097Valentin Legras

Sunburst Plots for Analyzing the Impact of Drugs on CRS

Wednesday 15:20-16:50

II-098Cristina Leon

Enhancing statistical power in lipid-lowering therapy studies through optimization of the MACE endpoint composition: a model-based meta-analysis approach

Wednesday 15:20-16:50

II-099Antonia Leonhardt

Towards MIPD of Linezolid: External Evaluation of Population Pharmacokinetic Models

Wednesday 15:20-16:50

II-100Raphaëlle Lesage

A quantitative system toxicology model of thyroid hormones for assessment of species differences in thyroid toxicity

Wednesday 15:20-16:50

II-101Giulia Lestini

Population pharmacokinetics and pharmacodynamics modeling of complement biomarkers and endpoints in C3 glomerulopathy (C3G) patients treated with iptacopan (FABHALTA®)

Wednesday 15:20-16:50

II-102Yingxue Li

Population Pharmacokinetic Modelling of Norepinephrine in Healthy Volunteers Prior to and During General Anesthesia

Wednesday 15:20-16:50

II-103Yu-Jou Lin

Model-informed once-daily dosing strategy for children, adolescents and adults for bedaquiline and delamanid

Wednesday 15:20-16:50

II-104Yu-wei Lin

Assessing the impact of choosing different estimated glomerular filtration rate (eGFR) equations on pharmacokinetic models: A proof-of-concept study with illustrative examples

Wednesday 15:20-16:50

II-105Andreas Lindauer

A Mini-Tutorial on Campsis: The R-Based PK/PD Simulation Suite

Wednesday 15:20-16:50

II-106Klaus Lindauer

Application of neural-ODE framework to support dose escalation decision during safety review meetings in first-in-human clinical trial

Wednesday 15:20-16:50

II-107Han Liu

Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials

Wednesday 15:20-16:50

II-108CHENYAO LIU

Population Pharmacokinetic of ketamine and norketamine in pediatric subjects during analgosedation

Wednesday 15:20-16:50

II-109Xuanlin Liu

Viral dynamic modeling of nirmatrelvir against SARS-CoV-2 in an in vitro infection model

Wednesday 15:20-16:50

II-110Sarah Lobet

Revealing the complexity of monoclonal antibodies exposure-response relationship in metastatic colorectal cancer patients while mitigating confounding factors

Wednesday 15:20-16:50

II-111Helena Loer

Unraveling the CYP2D6 Drug-Drug-Gene Interaction Network: A Comprehensive PBPK Analysis of Key Substrates and Inhibitors

Wednesday 15:20-16:50

II-112Ioannis Loisios-Konstantinidis

Physiologically based pharmacokinetic modeling and simulations to characterize the effect of cyclodextrins on the exposure of asciminib in lieu of clinical trials

Wednesday 15:20-16:50

II-113Orphélie Lootens

Unlocking Diversity: Towards a Comprehensive Framework for Physiologically Based Pharmacokinetic Population Qualification in Sub Saharan Africa

Wednesday 15:20-16:50

II-114Lorenzo Cifelli

ODE-free survival modeling with full pharmacokinetic profiles in the IMPRES-M framework

Wednesday 15:20-16:50

II-115Mark Lovern

Introducing InSilicoTrials NONMEM simulator: Cloud-based simulation tool for NONMEM models

Wednesday 15:20-16:50

II-116Esther Lubberts

The potential of modeling and simulation as support for generic long-acting injectable (LAI) marketing authorization applications

Wednesday 15:20-16:50